Molfarnate is difarnesyl compound patented by Kotobuki Seiyaku as an antiulcer and anti-inflammatory agent. In combination with a bisphosphonate, Molfarnate may also be useful for osteoporosis treatment.

Mofoxime is a phenoxyalkylcarboxylic acid derivative patented by Orchimed S. A. as a neurotropic and anti-inflammatory compound.

Eticyclidine (N-ethyl-1-phenylcyclohexylamine) is a phencyclidine derivative exerting nearly the same pharmacological profile as the parent compound. In rodents, it induces stereotypy, ataxia, interoceptive effect and hypothermia.

Nitrafudam is an antidepressant.

Nisoxetine, 3-(o-methoxyphenoxy)-3-phenyl-N-methyl-propyl-amine, is a most active and selective inhibitor of norepinephrine uptake, which was developed by Eli Lilly as an antidepressant drug. It was shown that nisoxetine dose-dependently reduced acute food intake and the additive effect of it was preserved in obese mice. In addition, was revealed that nisoxetine produced local but not systemic analgesia against cutaneous nociceptive stimuli in rodents. However, this drug has no clinical applications in humans.

Niprofazone is an anti-inflammatory analgesic.

Nimidane is a veterinary acaricide, tickicide.

Pyrroliphene is a dialkylaminodiphenylbutanol ester with antitussive and analgesic activities. In clinical trials the major side effect of Pyrroliphene was sedation, and the other side effect liabilities were similar to those of morphine.

Clorethate is a hypnotic sedative drug, discovered by SmithKline in the 1960s. In mice, oral administration the drug leads to depression of spontaneous motor activity with ED50 of 288 mg/kg.

Trigevolol is a beta-adrenergic blocking agent. It was developed as an antiarrhythmic and antihypertensive drug.